目次

Table of Content

1. Introduction to Cancer Antibody Combinations
1.1 History, Development and Evolution
1.2 Approved Cancer Antibody Combinations

2. Need of Antibody Combinations

3. Global Cancer Antibody Combinations Market and Clinical Development Insight
3.1 Current Market Scenario
3.2 Future Outlook

4. Global Antibody Combinations Market Insight by Region
4.1 US
4.2 China
4.3 Europe
4.4 Japan
4.5 UK
4.6 Canada
4.7 South Korea

5. Global Cancer Antibody Combinations Clinical Trials Overview
5.1 By Antibody Classification
5.2 By Breakthrough Therapy and Fast Track Status
5.3 By Company
5.4 By Country
5.5 By Indication
5.6 By Phase

6. Global Antibody Combinations Market Insight by Indication
6.1 Lung Cancer
6.2 Melanoma
6.3 Breast Cancer
6.4 Hepatocellular Cancer
6.5 Colorectal Cancer
6.6 Renal Cell Carcinoma
6.7 Lymphoma
6.8 Leukemia
6.9 Multiple Myeloma

7. Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country and Indication

9. Antibody - Antibody Combinations - Pricing, Patent and Dosing Insight
9.1 Opdivo + Yervoy
9.1.1 Overview and Patent Insight
9.1.2 Pricing and Dosage Insight
9.2 Opdualag (nivolumab and relatlimab)
9.2.1 Overview and Patent Insight
9.2.2 Pricing and Dosage Insight
9.3 Imjudo + Imfinzi
9.3.1 Overview and Patent Insight
9.3.2 Pricing and Dosage Insight

10. Antibody - Small Molecule Inhibitors Combinations - Pricing, Patent and Dosing Insight
10.1 Gazyva + Imbruvica
10.1.1 Overview and Patent Insight
10.1.2 Pricing and Dosage Insight
10.2 Imbruvica + Rituximab
10.2.1 Overview and Patent Insight
10.2.2 Pricing and Dosage Insight
10.3 Bavencio + Inlyta
10.3.1 Overview and Patent Insight
10.3.2 Pricing and Dosage Insight

11. Antibody - Immunomodulatory Agents Combinations - Pricing, Patent and Dosing Insight
11.1 Monjuvi + lenalidomide
11.1.1 Overview and Patent Insight
11.1.2 Pricing and Dosage Insight
11.2 Avastin + Interferon-alfa
11.2.1 Overview and Patent Insight
11.2.2 Pricing and Dosage Insight

12. Antibody - Chemotherapy Combinations - Pricing, Patent and Dosing Insight
12.1 Jemperli
12.1.1 Overview and Patent Insight
12.1.2 Pricing and Dosage Insight
12.2 Cyramza
12.2.1 Overview and Patent Insight
12.2.2 Pricing and Dosage Insight
12.3 Portrazza
12.3.1 Overview and Patent Insight
12.3.2 Pricing and Dosage Insight

13. Antibody - Mixed Combinations
13.1 Phesgo (Perjeta + Herceptin + hyaluronidase)
13.1.1 Overview and Patent Insight
13.1.2 Pricing and Dosage Insight
13.2 Darzalex
13.2.1 Overview and Patent Insight
13.2.2 Pricing and Dosage Insight
13.3 Empliciti
13.3.1 Overview and Patent Insight
13.3.2 Pricing and Dosage Insight

14. Competitive Landscape
14.1 AbbVie
14.2 Adagene
14.3 Agenus
14.4 Akeso Biopharma
14.5 Amgen
14.6 AstraZeneca
14.7 BeiGene
14.8 Biocad
14.9 BioInvent International
14.10 Bio-Thera Solutions
14.11 Boehringer Ingelheim
14.12 Bristol-Myers Squibb
14.13 Concentra Biosciences
14.14 Daiichi Sankyo Company
14.15 Eli Lilly and Company
14.16 Eucure Biopharma
14.17 Genentech
14.18 Genmab
14.19 GSK
14.20 ImmunoGen
14.21 Innovent Biologics
14.22 Janssen Research and Development
14.23 Jiangsu Hengrui Medicine Co.
14.24 LaNova Medicines Limited
14.25 Lepu Biopharma
14.26 MacroGenics
14.27 Merck
14.28 Merus
14.29 NGM Biopharmaceuticals
14.30 Novartis
14.31 Pfizer
14.32 Regeneron Pharmaceuticals
14.33 Roche
14.34 Seagen
14.35 Shanghai Henlius Biotech
14.36 Shanghai Junshi Biosciences
14.37 Sinocelltech
14.38 Symphogen
14.39 UCB
14.40 Xencor

List of Figures & Tables
Figure 1-1: Developmental Milestones for Antibody Combinations
Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination Therapy
Figure 2-2: Need of Antibody Combinations
Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
Figure 2-4: Expected Antibody Combinations
Figure 3-1: Global - Cancer Antibody Combination Market Opportunity (US$ Billion), 2023 - 2028
Figure 3-2: Antibody Combination Market - Prominent Regions
Figure 3-3: Aspects of Current Antibody Combinations Market
Figure 3-4: Future Characteristics of Antibody Combinations Market
Figure 4-1: COMBI-i Phase III Study - Initiation and Completion Years
Figure 4-2: CONTACT-01 Phase III Study - Initiation and Completion Years
Figure 4-3: NCT05800015 Phase II//III Study - Initiation and Completion Years
Figure 4-4: MagnetisMM-4 Phase II Study - Initiation and Completion Years
Figure 4-5: DREAMM 6 Phase I/II Study - Initiation and Completion Years
Figure 4-6: NCT04421352 Phase I Study - Initiation and Completion Year
Figure 4-7: NCT05867121 Phase I Study - Initiation and Completion Year
Figure 4-8: NCT06054477 Phase I/II Study - Initiation and Completion Year
Figure 4-9: NCT04868877 Phase I/II Study - Initiation and Completion Year
Figure 4-10: NCT05867121 Phase I Study - Initiation and Completion Year
Figure 4-11: NCT06038578 Phase II Study - Initiation and Completion Year
Figure 4-12: DESTINY-Breast01 Phase II Study - Initiation and Completion Year
Figure 4-13: BI-1607 and Trastuzumab Phase I/II Study - Initiation and Completion Year
Figure 4-14: Myechild01 Phase III Study - Initiation and Completion Year
Figure 4-15: GS-9911 and Zimberelimab Phase I Study - Initiation and Completion Year
Figure 4-16: EGIA-002 Phase II Study - Initiation and Completion Year
Figure 4-17: TUC1PI-01 Phase I/II Study - Initiation and Completion Year
Figure 4-18: TUC1PI-01 Phase I/II Study - Initiation and Completion Year
Figure 4-19: LEAP-008 Phase III Study - Initiation and Completion Year
Figure 4-20: VOLGA Phase III Study - Initiation and Completion Year
Figure 4-21: MarkV-01 Phase I Study - Initiation and Completion Year
Figure 5-1: Global - Cancer Antibody Combinations Clinical Trials By Antibody Classification, 2023 till 2028
Figure 5-2: Global - Cancer Antibody Combinations Clinical Trials By Priority Status, 2023 till 2028
Figure 5-3: Global - Cancer Antibody Combinations Clinical Trials By Company, 2023 till 2028
Figure 5-4: Global - Cancer Antibody Combinations Clinical Trials By Country, 2023 till 2028
Figure 5-5: Global - Cancer Antibody Combinations Clinical Trials By Indication, 2023 till 2028
Figure 5-6: Global - Cancer Antibody Combinations Clinical Trials By Phase, 2023 till 2028
Figure 6-1: Lung Cancer - Approved Antibody Combinations
Figure 6-2: Cemiplimab and Fianlimab Phase II/III Study - Initiation and Completion Year
Figure 6-3: Daratumumab, Nivolumab and KRAS vaccine Phase II Study - Initiation and Completion Year
Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations
Figure 6-5: Melanoma - Approved Antibody Combinations
Figure 6-6: NCT05608291 Phase III Study - Initiation and Completion Year
Figure 6-7: OrienX010-II-11 Phase I Study - Initiation and Completion Year
Figure 6-8: MM1636 Phase I/II Study - Initiation and Completion Year
Figure 6-9: Breast Cancer - Approved Antibody Combinations
Figure 6-10: Trastuzumab and Pyrotinib Phase III Study - Initiation and Completion Year
Figure 6-11: Inetetamab, Toripalimab and Paclitaxel Phase IV Study - Initiation and Completion Year
Figure 6-12: Breast Cancer - Key Player in Antibody Combination Commercial Market
Figure 6-13: Breast Cancer - Different Antibody Combination With Other Therapeutic Agents
Figure 6-14: Hepatocellular Cancer- Approved Antibody Combinations
Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular Carcinoma
Figure 6-16: Penpulimab and Anlotinib Phase III Study - Initiation and Completion Year
Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company
Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer
Figure 6-19: NCT06099951 Phase II Study - Initiation and Completion Year
Figure 6-20: KEYFORM-007 Phase III Study - Initiation and Completion Year
Figure 6-21: Renal Cell Carcinoma - Approved Antibody Combinations
Figure 6-22: SillaJen and Regeneron Pharmaceuticals - Novel Approach of Combining Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
Figure 6-23: BMC128 and Nivolumab Phase I Study - Initiation and Completion Year
Figure 6-24: Lymphoma - Approved Antibody Combinations
Figure 6-25: NCT04464798 Phase I Study - Initiation and Completion Year
Figure 6-26: Odronextamab, Lenalidomide and Rituximab Phase III Study - Initiation and Completion Year
Figure 6-27: L-DEP and PD-1 Antibody Phase III Study - Initiation and Completion Year
Figure 6-28: Collaboration of MorphoSys and Incyte, IGM Bioscience and ADC Therapeutic, 2022
Figure 6-29: Leukemia - Approved Antibody Combinations
Figure 6-30: NCT06043674 Phase II Study - Initiation and Completion Year
Figure 6-31: NP137, Venetoclax and Azacitidine Phase I/II Study - Initiation and Completion Year
Figure 6-32: Novartis - Hypothesis for Phase 3 Clinical Study
Figure 6-33: Sabatolimab and Azacitidine Phase III Study - Initiation and Completion Year
Figure 6-34: Multiple Myeloma - Approved Antibody Combinations
Figure 6-35: NCT05730036 Phase III Study - Initiation and Completion Year
Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple Myeloma
Figure 6-37: NCT05363111 Phase I Study - Initiation and Completion Year
Figure 9-1: Opdivo and Yervoy - Minimum Market Exclusivity Year by Region
Figure 9-2: Opdivo and Yervoy - FDA Approval Years by Indications
Figure 9-3: Opdivo and Yervoy - EMA Approval Years by Indications
Figure 9-4: US - Opdivo Cost per Unit and Supply (US$), December’2023
Figure 9-5: US - Yervoy Cost per Unit and Supply (US$), December’2023
Figure 9-6: EU - Opdivo Cost of Supply (US$), November’2023
Figure 9-7: EU - Yervoy Cost of Supply (US$), November’2023
Figure 9-8: Opdualag - Approval Years by Region
Figure 9-9: Opdualag - Minimum Market Exclusivity Year by Region
Figure 9-10: US and EU - Opdualag Cost per Supply (US$), November’2023
Figure 9-11: Imfinzi and Imjudo - Patent Expiry Years by Region
Figure 9-12: US - Imfinzi Cost per Unit and Supply (US$), November’2023
Figure 9-13: US - Imjudo Cost per Unit and Supply (US$), November’2023
Figure 9-14: EU - Imfinzi Cost per Unit and Supply (US$), November’2023
Figure 9-15: EU - Imjudo Cost per Unit and Supply (US$), November’2023
Figure 9-16: US - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 9-17: US - Padcev Cost per Unit and Supply (US$), November’2023
Figure 9-18: EU - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 9-19: EU - Padcev Cost per Unit and Supply (US$), November’2023
Figure 9-20: US - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 9-21: US - Herceptin Cost per Unit and Supply (US$), November’2023
Figure 9-22: US - Trastuzumab Biosimilar Cost per Unit and Supply (US$), November’2023
Figure 9-23: EU - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 9-24: US - Tecentriq Cost per Unit and Supply (US$), November’2023
Figure 9-25: US - Avastin Cost per Unit and Supply (US$), November’2023
Figure 9-26: US - Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$), November’2023
Figure 9-27: US - Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$), November’2023
Figure 9-28: US - Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml and 160ml (US$), November’2023
Figure 9-29: EU - Tecentriq Cost per Unit and Supply (US$), November’2023
Figure 9-30: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), November’2023
Figure 9-31: US - Perjeta Cost per Unit and Supply (US$), November’2023
Figure 9-32: US - Herceptin Cost per Unit and Supply (US$), November’2023
Figure 9-33: US - Trastuzumab Biosimilar Cost per Unit and Supply (US$), November’2023
Figure 9-34: EU - Perjeta Cost per Supply (US$), November’2023
Figure 9-35: US - Polivy Cost per Supply (US$), November’2023
Figure 9-36: US - Rituxan Cost per Unit and Supply (US$), November’2023
Figure 9-37: US - Rituximab Biosimilar Cost per Unit and Supply of 10ml (US$), November’2023
Figure 9-38: US - Rituximab Biosimilar Cost per Unit and Supply of 50ml (US$), November’2023
Figure 9-39: EU - Polivy Cost per Supply (US$), November’2023
Figure 9-40: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November’2023
Figure 10-1: US - Imbruvica Cost per Unit and Supply of 70mg (US$), November’2023
Figure 10-2: US - Imbruvica Cost per Unit and Supply of 140mg (US$), November’2023
Figure 10-3: US - Gazyva Cost per Unit and Supply (US$), November’2023
Figure 10-4: US - Imbruvica Cost per Unit and Supply of 70mg (US$), November’2023
Figure 10-5: US - Imbruvica Cost per Unit and Supply of 140mg (US$), November’2023
Figure 10-6: US - Rituxan Cost per Unit and Supply (US$), November’2023
Figure 10-7: US - Rituximab Biosimilar Cost per Unit and Supply of 10ml (US$), November’2023
Figure 10-8: US - Rituximab Biosimilar Cost per Unit and Supply of 50ml (US$), November’2023
Figure 10-9: EU - Rituximab Biosimilar Truxima Cost per Supply (US$), November’2023
Figure 10-10: US - Bavencio Cost per Unit and Supply (US$), November’2023
Figure 10-11: US - Inlyta Cost per Unit and Supply (US$), November’2023
Figure 10-12: EU - Bavencio Cost per Unit and Supply (US$), November’2023
Figure 10-13: EU - Inlyta Cost per Unit and Supply (US$), November’2023
Figure 10-14: US - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 10-15: US - Inlyta Cost per Unit and Supply (US$), November’2023
Figure 10-16: EU - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 10-17: EU - Inlyta Cost per Unit and Supply (US$), November’2023
Figure 10-18: US - Cyramza Cost per Unit and Supply (US$), December’2023
Figure 10-19: US - Tarceva Cost per Supply (US$), December’2023
Figure 10-20: EU - Cyramza Cost per Unit and Supply (US$), December’2023
Figure 10-21: US - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 10-22: US - Lenvima Cost per Unit and Supply (US$), November’2023
Figure 10-23: EU - Keytruda Cost per Unit and Supply (US$), December’2023
Figure 10-24: US - Opdivo Cost per Unit and Supply (US$), November’2023
Figure 10-25: US - Cabometyx Cost per Unit and Supply (US$), November’2023
Figure 10-26: EU - Opdivo Cost per Unit and Supply (US$), November’2023
Figure 10-27: EU - Cabometyx Cost per Unit and Supply (US$), November’2023
Figure 11-1: US - Monjuvi Cost of Supply (US$), December’2023
Figure 11-2: US - Revlimid Cost per Unit and Supply (US$), December’2023
Figure 11-3: US - Avastin Cost per Unit and Supply (US$), December’2023
Figure 11-4: US - Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$), December’2023
Figure 11-5: US - Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$), December’2023
Figure 11-6: US - Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml and 160ml (US$), December’2023
Figure 11-7: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December’2023
Figure 12-1: US and EU - Jemperli Cost of Supply (US$), December’2023
Figure 12-2: US - Paclitaxel Cost per Unit and Supply (US$), December’2023
Figure 12-3: US - Paraplatin Cost per Unit and Supply (US$), December’2023
Figure 12-4: US - Carboplatin Cost per Unit and Supply (US$), December’2023
Figure 12-5: US - Cyramza Cost per Unit and Supply (US$), December’2023
Figure 12-6: EU - Cyramza Cost per Unit and Supply (US$), December’2023
Figure 12-7: US - Taxotere Cost per Unit and Supply (US$), December’2023
Figure 12-8: US - Paclitaxel Cost per Unit and Supply (US$), December’2023
Figure 12-9: US and EU - Cyramza Cost per Unit and Supply (US$), December’2023
Figure 12-10: US - Gemzar Cost of Supply (US$), December’2023
Figure 12-11: US - Infugem Cost per Unit and Supply (US$), December’2023
Figure 12-12: US - Cisplatin Cost per Unit and Supply for Intravenous Solution (US$), December’2023
Figure 12-13: US - Vectibix Cost per Unit and Supply (US$), December’2023
Figure 12-14: US - Eloxatin Cost per Unit and Supply (US$), December’2023
Figure 12-15: US - Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$), December’2023
Figure 12-16: US - Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-17: US - Adrucil Cost per Unit and Supply (US$), December’2023
Figure 12-18: US - Fluorouracil Cost per Unit and Supply (US$), December’2023
Figure 12-19: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-20: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, and 500mg/ml (US$), December’2023
Figure 12-21: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-22: US - Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$), December’2023
Figure 12-23: US - Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$), December’2023
Figure 12-24: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-25: US - Adriamycin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-26: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-27: US - Doxorubicin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-28: US - Vincristine Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-29: US - Toposar Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-30: US - Etoposide Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-31: US - Etoposide Cost per Unit and Supply of Oral Capsule (US$), December’2023
Figure 12-32: US - Prednisone Cost per Unit and Supply of 1mg/ml Oral Solution (US$), December’2023
Figure 12-33: US - Prednisone Cost per Unit and Supply of 5mg/ml Oral Solution (US$), December’2023
Figure 12-34: US - Prednisone Cost per Unit and Supply of 1mg Oral Tablet (US$), December’2023
Figure 12-35: US - Prednisone Cost per Unit and Supply of 2.5mg Oral Tablet (US$), December’2023
Figure 12-36: US - Prednisone Cost per Unit and Supply of 5mg Oral Tablet (US$), December’2023
Figure 12-37: US - Prednisone Cost per Unit and Supply of 50mg Oral Tablet (US$), December’2023
Figure 12-38: US - Prednisone Cost per Unit and Supply of 10mg Oral Tablet (US$), December’2023
Figure 12-39: US - Prednisone Cost per Unit and Supply of 20mg Oral Tablet (US$), December’2023
Figure 12-40: US - Vinblastine Cost per Unit and Supply (US$), December’2023
Figure 12-41: US - Dacarbazine Cost per Unit and Supply for 100mg Intravenous Powder (US$), December’2023
Figure 12-42: US - Dacarbazine Cost per Unit and Supply for 200mg Intravenous Powder (US$), December’2023
Figure 12-43: US - Erbitux Cost per Unit and Supply (US$), December’2023
Figure 12-44: US - Camptosar Cost per Unit and Supply (US$), December’2023
Figure 12-45: US - Irinotecan Cost per Unit and Supply (US$), December’2023
Figure 12-46: US - Cisplatin Cost per Unit and Supply for Intravenous Solution (US$), December’2023
Figure 12-47: US - Paraplatin Cost per Unit and Supply (US$), December’2023
Figure 12-48: US - Carboplatin Cost per Unit and Supply (US$), December’2023
Figure 12-49: US - Adrucil Cost per Unit and Supply (US$), December’2023
Figure 12-50: US - Fluorouracil Cost per Unit and Supply (US$), December’2023
Figure 12-51: US - Leucovorin Cost of Supply of 100mg, 200mg, 350mg and 500mg Injectable Powder (US$), December’2023
Figure 12-52: US - Leucovorin Cost per Unit and Supply of Injectable Solution (US$), December’2023
Figure 12-53: US - Leucovorin Cost per Unit and Supply of 5mg Oral Tablet (US$), December’2023
Figure 12-54: US - Leucovorin Cost per Unit and Supply of 10mg Oral Tablet (US$), December’2023
Figure 12-55: US - Leucovorin Cost per Unit and Supply of 15mg Oral Tablet (US$), December’2023
Figure 12-56: US - Leucovorin Cost per Unit and Supply of 25mg Oral Tablet (US$), December’2023
Figure 12-57: US - Avastin Cost per Unit and Supply (US$), December’2023
Figure 12-58: US - Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$), December’2023
Figure 12-59: US - Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$), December’2023
Figure 12-60: US - Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml and 160ml (US$), December’2023
Figure 12-61: EU - Bevacizumab Biosimilar Vegzelma Cost per Supply (US$), December’2023
Figure 12-62: US - Paclitaxel Cost per Unit and Supply (US$), December’2023
Figure 12-63: US - Paraplatin Cost per Unit and Supply (US$), December’2023
Figure 12-64: US - Carboplatin Cost per Unit and Supply (US$), December’2023
Figure 12-65: US - Tecentriq Cost per Unit and Supply (US$), November’2023
Figure 12-66: US - Gemzar Cost of Supply (US$), December’2023
Figure 12-67: US - Infugem Cost per Unit and Supply (US$), December’2023
Figure 12-68: US - Hycamtin Cost of Supply of Oral Capsule (US$), December’2023
Figure 12-69: US - Topotecan Cost of Supply of Intravenous Solution (US$), December’2023
Figure 12-70: US - Keytruda Cost per Unit and Supply (US$), November’2023
Figure 12-71: EU - Keytruda Cost of Supply (US$), November’2023
Figure 12-72: US - Xeloda Cost per Unit and Supply (US$), November’2023
Figure 12-73: US - Capecitabine Cost per Unit and Supply of 150mg (US$), November’2023
Figure 12-74: US - Capecitabine Cost per Unit and Supply of 500mg (US$), November’2023
Figure 12-75: US - Adrucil Cost per Unit and Supply (US$), December’2023
Figure 12-76: US - Fluorouracil Cost per Unit and Supply (US$), December’2023
Figure 12-77: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-78: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml, and 500mg/ml (US$), December’2023
Figure 12-79: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-80: US - Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$), December’2023
Figure 12-81: US - Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$), December’2023
Figure 12-82: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-83: US - Adriamycin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-84: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-85: US - Doxorubicin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-86: US - Paclitaxel Cost per Unit and Supply (US$), December’2023
Figure 12-87: US - Abraxane Cost per Unit and Supply (US$), December’2023
Figure 12-88: US - Cisplatin Cost per Unit and Supply for Intravenous Solution (US$), December’2023
Figure 12-89: US - Paraplatin Cost per Unit and Supply (US$), December’2023
Figure 12-90: US - Carboplatin Cost per Unit and Supply (US$), December’2023
Figure 12-91: US - Eloxatin Cost per Unit and Supply (US$), December’2023
Figure 12-92: US - Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$), December’2023
Figure 12-93: US - Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-94: US - Gemzar Cost of Supply (US$), December’2023
Figure 12-95: US - Infugem Cost per Unit and Supply (US$), December’2023
Figure 12-96: US - Gemcitabine Cost of Supply of Intravenous Powder for Injection (US$), December’2023
Figure 12-97: US - Gemcitabine Cost per Unit and Supply of 38mg/ml Intravenous Solution (US$), December’2023
Figure 12-98: US - Gemcitabine Cost per Unit and Supply of 100mg/ml Intravenous Solution (US$), December’2023
Figure 12-99: US - Alimta Cost of Supply (US$), December’2023
Figure 12-100: US - Pemfexy Cost per Unit and Supply (US$), December’2023
Figure 12-101: US - Pemetrexed Cost per Unit and Supply of Intravenous Powder for Injection (US$), December’2023
Figure 12-102: US - Pemetrexed Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-103: US - Ellence Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-104: US - Epirubicin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-105: US - Herceptin Cost per Unit and Supply (US$), November’2023
Figure 12-106: US - Trastuzumab Biosimilar Cost per Unit and Supply (US$), November’2023
Figure 12-107: US - Xeloda Cost per Unit and Supply (US$), November’2023
Figure 12-108: US - Capecitabine Cost per Unit and Supply of 150mg (US$), November’2023
Figure 12-109: US - Capecitabine Cost per Unit and Supply of 500mg (US$), November’2023
Figure 12-110: US - Adrucil Cost per Unit and Supply (US$), December’2023
Figure 12-111: US - Fluorouracil Cost per Unit and Supply (US$), December’2023
Figure 12-112: US - Cyclophosphamide Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-113: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Doses 1g/2ml, 2g/4ml and 500mg/ml (US$), December’2023
Figure 12-114: US - Cyclophosphamide Cost per Unit and Supply of Intravenous Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-115: US - Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$), December’2023
Figure 12-116: US - Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$), December’2023
Figure 12-117: US - Adriamycin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-118: US - Adriamycin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-119: US - Doxorubicin Cost of Supply of Intravenous Powder (US$), December’2023
Figure 12-120: US - Doxorubicin Cost per Unit and Supply of Intravenous Solution (US$), December’2023
Figure 12-121: US - Cisplatin Cost per Unit and Supply for Intravenous Solution (US$), December’2023
Figure 12-122: US - Paclitaxel Cost per Unit and Supply (US$), December’2023
Figure 12-123: US - Libtayo Cost per Unit and Supply (US$), December’2023
Figure 12-124: US - Libtayo Cost per Unit and Supply (US$), December’2023
Figure 12-125: US - Cisplatin Cost per Unit and Supply for Intravenous Solution (US$), December’2023
Figure 12-126: US - Paraplatin Cost per Unit and Supply (US$), December’2023
Figure 12-127: US - Carboplatin Cost per Unit and Supply (US$), December’2023
Figure 12-128: US - Eloxatin Cost per Unit and Supply (US$), December’2023
Figure 12-129: US - Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$), December’2023
Figure 12-130: US - Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$),December’2023
Figure 13-1: US - Phesgo Cost per Unit and Supply (US$), December’2023
Figure 13-2: EU - Phesgo Cost per Unit and Supply (US$), December’2023
Figure 13-3: US - Darzalex Cost per Unit and Supply (US$), November’2023
Figure 13-4: EU - Darzalex Cost per Unit and Supply (US$), December’2023
Figure 13-5: US - Kyprolis Cost per Unit and Supply (US$), November’2023
Figure 13-6: US - Dexamethasone Cost per Unit and Supply of 4mg/ml Injectable Solution (US$), December’2023
Figure 13-7: US - Dexamethasone Cost per Unit and Supply of 10mg/ml Injectable Solution (US$), December’2023
Figure 13-8: US - Dexamethasone Cost per Unit and Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023
Figure 13-9: US - Dexamethasone Cost per Unit and Supply of Oral Liquid (US$), December’2023
Figure 13-10: US - Dexamethasone Cost per Unit and 100-Tablet Supply of 0.5mg, 1mg and 6mg Oral Tablets (US$), December’2023